Medication-Assisted Treatment (MAT)
Our national initiative seeks to increase the use of acamprosate, naltrexone (both in oral and injectable form), buprenorphine-and new medications as their proven benefits emerge-in treatment of substance use disorders where clinically appropriate. The program not only focuses on patients who have been discharged from inpatient substance use treatment programs, but also targets individuals receiving outpatient case or disease management services. Through MAT measures, Magellan monitors the number of cases in which physicians are prescribing medications and follows member readmission rates.
As part of this intervention, Magellan continually collaborates with its health plan partners to help facilitate the incorporation of these medications into client formularies. Additionally, Magellan focuses on provider education efforts to illustrate the importance of using appropriate medications when developing members' substance use disorder treatment plans.
More information and support documents can be found on our Magellan Provider website.